- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01560221
Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution
10 de dezembro de 2014 atualizado por: Anthony DeFulio, Johns Hopkins University
The combination of using injection drugs, smoking crack cocaine, having multiple sex partners, and inconsistent condom use results in substantial risk for acquiring and transmitting HIV, and many drug dependent adults who have been arrested on charges of prostitution fit this profile.
Existing interventions for reducing HIV risk have had limited efficacy in drug-dependent sex workers, and criminal justice approaches have been ineffective despite their high cost.
A potentially ideal alternative is to divert drug-dependent arrestees from prosecution to a treatment that reduces drug use and HIV sex risk behaviors, while providing job skills training and promoting community employment to alleviate the financial need to continue sex work.
In order to provide an effective therapeutic alternative to criminal prosecution, the investigators propose to develop a multifaceted intervention that includes opiate agonist treatment (i.e., methadone OR buprenorphine) and the Therapeutic Workplace.
The Therapeutic Workplace is a supported environment in which participants are required to provide drug-free urine samples to access paid job skills training or employment and to maintain the maximum rate of pay.
The overall intervention is designed to reduce drug use and HIV risk behaviors, and simultaneously promote employment.
The proposed project is a 2-year Stage I behavior therapy development effort that will include the development, manualization and pilot testing of a Therapeutic Workplace intervention tailored to drug-dependent adults arrested for prostitution.
In the pilot study, the investigators will recruit opiate- and cocaine-dependent adults arrested for prostitution from the Eastside District Court in Baltimore.
Eligible individuals will be offered methadone treatment in lieu of prosecution and will be required to remain in methadone treatment for 90 days to have the charges against them dropped.
After enrolling in opiate agonist treatment, the diverted individuals will be invited to participate in the pilot study.
Interested individuals will be randomly assigned to receive the standard opiate agonist treatment services or these services plus the Therapeutic Workplace.
The Therapeutic Workplace has two phases.
In Phase 1, participants will be offered four months of stipend-supported job training in the Therapeutic Workplace.
In Phase 2, participants will be encouraged to seek employment in a community job and will receive wage subsidies for four months for maintaining community employment or engaging in supervised job seeking.
Throughout both phases, participants will be required to provide drug-free urine samples to receive Therapeutic Workplace wages (training stipends in Phase 1 and wage subsidies in Phase 2).
The wage subsidy program will include drug testing managed by a national supplier of drug-free workplace services.
Overall, this treatment could serve as a novel and ideal intervention for drug-dependent adults arrested for prostitution while reducing criminal justice costs.
Visão geral do estudo
Status
Concluído
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
38
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- The Center for Learning and Health
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 65 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion criteria:
- Opioid dependent
- Adults
- Recently arrested
- Have a pending charge of prostitution or perverted practice
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Therapeutic Workplace
Participants will receive all standard services plus the Therapeutic Workplace intervention, in which access to stipend supported training and/or wage subsidies for community employment is contingent upon drug abstinence as verified by urinalysis.
|
Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment.
Access to training and employment is contingent upon meeting therapeutic targets.
Potential targets include, but are not limited to, drug abstinence and medication adherence.
Methadone in liquid form, with the dosage determined by physician on an individual basis.
Anticipated dose range 30mg to 100mg daily.
Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence.
Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
Outros nomes:
|
|
Comparador Ativo: Standard Services
Participants will receive methadone treatment or buprenorphine treatment, depending upon medical recommendations of their physicians, slot availability, and their own preferences.
Participants who remain in treatment for at least 90 days will have the charge of prostitution that is pending against them dropped.
|
Methadone in liquid form, with the dosage determined by physician on an individual basis.
Anticipated dose range 30mg to 100mg daily.
Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence.
Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Drug abstinence
Prazo: Participants will be followed for eight months. Drug abstinence will be measured every 30 days throughout the eight month period.
|
A combination of urinalysis and self-reports of illicit drug use.
This outcome is treated as dichotomous: Urine samples are considered positive or negative based on standard cutoffs for drugs of abuse, and self-reports are yes or no depending upon whether there was or was not any drug use in the previous 30 days.
|
Participants will be followed for eight months. Drug abstinence will be measured every 30 days throughout the eight month period.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
HIV Sex Risk
Prazo: Participants will be followed for eight months. HIV Sex Risk will be measured every 30 days throughout the eight month period.
|
The self-reported number of unprotected vaginal and anal sex occasions in the prior month.
|
Participants will be followed for eight months. HIV Sex Risk will be measured every 30 days throughout the eight month period.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Anthony DeFulio, Ph.D., Johns Hopkins University
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de outubro de 2012
Conclusão Primária (Real)
1 de dezembro de 2014
Conclusão do estudo (Real)
1 de dezembro de 2014
Datas de inscrição no estudo
Enviado pela primeira vez
15 de março de 2012
Enviado pela primeira vez que atendeu aos critérios de CQ
21 de março de 2012
Primeira postagem (Estimativa)
22 de março de 2012
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
11 de dezembro de 2014
Última atualização enviada que atendeu aos critérios de controle de qualidade
10 de dezembro de 2014
Última verificação
1 de dezembro de 2014
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Transtornos Mentais, Desordem Mental
- Distúrbios induzidos quimicamente
- Transtornos Relacionados a Substâncias
- Efeitos Fisiológicos das Drogas
- Depressores do Sistema Nervoso Central
- Agentes do Sistema Nervoso Periférico
- Analgésicos
- Agentes do Sistema Sensorial
- Analgésicos, Opioides
- Narcóticos
- Antagonistas Narcóticos
- Agentes do Sistema Respiratório
- Antitussígenos
- Buprenorfina
- Metadona
Outros números de identificação do estudo
- R34DA033141 (Concessão/Contrato do NIH dos EUA)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .